Financial Performance - The company's revenue for Q1 2022 reached ¥150,135,067.62, representing a significant increase of 3406.56% compared to the same period last year[6] - The net profit attributable to shareholders was -¥286,830,516.15, reflecting a decrease of 55.48% year-over-year[7] - The net cash flow from operating activities was -¥350,478,067.32, a decline of 29.06% compared to the previous year[7] - The basic earnings per share were -¥0.59, a decrease of 56.91% year-over-year[7] - Net loss for Q1 2022 was ¥286,830,516.15, compared to a net loss of ¥184,482,710.79 in Q1 2021[26] - Basic and diluted earnings per share for Q1 2022 were both -¥0.59, compared to -¥0.38 in Q1 2021[27] Operating Costs and Expenses - The operating costs surged by 7585.76% due to increased sales costs associated with new product launches[11] - Total operating costs for Q1 2022 amounted to ¥438,730,733.58, compared to ¥195,520,624.96 in Q1 2021[25] - The company experienced a notable increase in operating expenses, with a rise of 8307.24% attributed to increased donations for drug donations and patient assistance programs[13] - The company reported a significant increase in personnel costs due to staff additions and rising wage levels, contributing to overall expenses[13] Research and Development - Research and development expenses totaled ¥218,173,558.62, an increase of 60.29% year-over-year[7] - Research and development expenses in Q1 2022 were ¥218,173,558.62, up from ¥136,115,384.97 in Q1 2021, indicating a focus on innovation[25] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[13] - The company is focusing on expanding its market presence and enhancing product offerings through ongoing research and development efforts[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,345,143,075.38, up 52.56% from the end of the previous year[7] - As of March 31, 2022, the company had total assets of approximately CNY 6.35 billion, up from CNY 4.16 billion at the end of 2021, reflecting a growth of about 53.5%[22] - Total liabilities as of Q1 2022 were ¥676,891,679.41, an increase from ¥712,787,425.02 in the previous period[24] - Shareholders' equity totaled ¥5,668,251,395.97 in Q1 2022, up from ¥3,446,421,451.58 in Q1 2021[24] Cash Flow - The company reported a decrease in cash flow from operating activities, reflecting challenges in cash generation[27] - The net cash flow from operating activities for Q1 2022 was -¥350,478,067.32, compared to -¥271,564,180.13 in Q1 2021, indicating a deeper cash outflow[30] - Total cash inflow from financing activities in Q1 2022 was ¥2,612,462,448.00, while cash outflow was ¥98,713,721.14, resulting in a net cash flow of ¥2,513,748,726.86[31] - The company's cash and cash equivalents at the end of Q1 2022 totaled ¥3,735,640,216.30, up from ¥2,194,813,283.64 at the end of Q1 2021[31] - The company reported a total cash outflow from operating activities of ¥466,158,621.88 in Q1 2022, compared to ¥329,254,831.22 in Q1 2021[30] Shareholder Information - The company issued a total of 189,581,239 shares in Hong Kong, accounting for 34.83% of the total share capital, and 354,681,764 shares on the Shanghai Stock Exchange, accounting for 65.17%[18] - The top ten shareholders held a combined 28.85% of the shares, with HKSCC NOMINEES LIMITED being the largest shareholder[14] Government Support and Other Income - The company reported government subsidies of ¥7,390,154.09, which were included in other income[8] - Cash received from tax refunds in Q1 2022 was ¥27,420,872.62, down from ¥39,351,502.71 in Q1 2021[29]
荣昌生物(09995) - 2022 Q1 - 季度财报